Lexaria forms CPG subsidiary Lexaria Nutraceutical, amends pharma license; nicotine study results due within 2 weeks

Lexaria Bioscience Corp.

New wholly-owned subsidiary Lexaria Nutraceutical Corp. receives exclusive perpetual license for DehydraTECH in consumer packaged goods (excluding cannabis/nicotine).
Lexaria Pharmaceutical Corp. license amended to focus solely on pharmaceutical products (excluding nicotine).
Human nicotine study NIC-H22-1 (36 smokers, crossover PK) completed dosing; results expected in ~2 weeks.
Oral nicotine pouch market was $2.33B in 2020, CAGR 30.7%, projected to reach $21.84B by 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.